Amarogentin

Amarogentin at a Glance

Amarogentin is a secoiridoid glycoside — a ring-opened iridoid glucoside — best known as the bitter principle of gentian and as one of the most bitter natural substances ever characterised, detectable in water diluted to roughly one part in 58 million ^{7Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. Its name is literally “gentian bitterness,” and although it is present only in trace amounts in gentian root, its extreme potency makes it the dominant contributor to the herb’s famous bitterness — the reference bitterant against which gentian’s quality has long been judged.

Beyond taste, amarogentin has a small but distinctive isolate research signal that sets it apart from most bitter glycosides: it is a naturally occurring inhibitor of Leishmania DNA topoisomerase I ^{1Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →} and a pro-apoptotic agent in preclinical cancer models ^{3,4Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →Reference 4Huang C et al. · 2017AnimalAmarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in miceView study →}. These are its most characteristic findings, and they are genuinely the isolated molecule — but they are entirely in-vitro and animal work.

Two honesty caveats run through the page. There are no human trials of isolated amarogentin; the human evidence for its source is for whole gentian (as a digestive bitter, and as a skin-barrier extract) ^{6,7Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. And like other polar secoiridoid glucosides, amarogentin is expected to be poorly absorbed orally, with no dedicated human pharmacokinetic data — a limit that undercuts how far its in-vitro potency can translate.

The Bitterest Natural Substance

Amarogentin is the compound most often cited as the bitterest naturally occurring substance known. Its bitter value — the classical pharmacognosy measure of how far a bitter can be diluted and still be tasted — is on the order of 58,000,000, meaning it remains clearly perceptible at a dilution of about 1:58,000,000 ^{7Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. (Some synthetic compounds, such as denatonium benzoate, are more bitter still, so amarogentin’s superlative is specifically among natural substances.)

What makes this remarkable is that amarogentin is present in gentian root only in trace quantity (~0.025–0.4% of the dried root), an order of magnitude below the more abundant secoiridoid gentiopicroside (~1–4%) ^{7Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. Because amarogentin is so vastly more potent per molecule, it is nonetheless the principal determinant of the root’s bitterness — and therefore the natural reference standard for gentian bitterness, the property that has defined the herb’s use as a digestive bitter for centuries.

Bitter-Receptor Pharmacology

At the receptor level, amarogentin is a broad agonist of human bitter taste receptors (TAS2Rs). It activates the orphan receptor hTAS2R50 — a receptor for which andrographolide and amarogentin were among the first natural agonists identified ^{5Reference 5Behrens M et al. · 2009The human bitter taste receptor hTAS2R50 is activated by the two natural bitter terpenoids andrographolide and amarogentinView study →} — and binds TAS2R1 and TAS2R38 in human keratinocytes ^{6Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →}. This promiscuity across several TAS2R subtypes is part of why its bitterness is so intense and so hard to mask.

TAS2Rs are not confined to the tongue. Extraoral bitter receptors in the gut, airway and skin mean an ultra-potent TAS2R agonist like amarogentin has plausible signalling roles beyond taste — the mechanistic basis both for the traditional bitter-secretagogue (“bitters stimulate digestion”) rationale and for the keratinocyte skin-barrier effects seen with gentian extract ^{6Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →}. These extraoral effects are, so far, whole-extract and in-vitro observations rather than demonstrated isolate therapeutics.

Antileishmanial & Anticancer Research

The isolate signals that make amarogentin more than a flavour molecule are its antiparasitic and anticancer preclinical findings — its most distinctive research thread, and squarely the isolated compound.

Antileishmanial (topoisomerase I). Amarogentin was isolated from Swertia chirata precisely by tracking inhibition of the type I DNA topoisomerase of Leishmania donovani, the parasite behind visceral leishmaniasis (kala-azar). It is a potent inhibitor of the enzyme, acting by preventing formation of the topoisomerase–DNA binary complex ^{1Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →}. In an infected hamster model, amarogentin delivered in liposomes and niosomes reduced parasite burden more effectively than the free compound — with the niosomal form the most active — and toxicity studies (blood pathology, liver enzymes) showed no toxicity ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}. Note the tell: efficacy in vivo required vesicular (parenteral) delivery, not oral dosing.

Anticancer / pro-apoptotic. In a chemically-induced mouse skin carcinogenesis model, amarogentin (from Swertia chirata) reduced hyperproliferation by downregulating COX-2 (Cox-II) and upregulating apoptosis (increased caspase-3, fewer proliferating cells) ^{3Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →}. In liver cancer, amarogentin selectively inhibited hepatocellular-carcinoma lines (HepG2, SMMC-7721) over normal liver cells and, in a mouse xenograft, induced apoptosis by upregulating p53 and downregulating human telomerase reverse transcriptase (hTERT), with suppression of Akt and NF-κB signalling ^{4Reference 4Huang C et al. · 2017AnimalAmarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in miceView study →}.

The honest frame: these are coherent, on-target isolate findings — a real antiparasitic mechanism and a reproducible pro-apoptotic theme — but they remain in-vitro and rodent. There are no human isolate trials for either indication, and the antileishmanial work depended on engineered delivery systems rather than the free, orally-dosed molecule ^{1,2,3,4Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →Reference 4Huang C et al. · 2017AnimalAmarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in miceView study →}.

What It's Used For

Amarogentin’s evidence base is small and splits cleanly: a whole-herb human tradition (bitter digestive; a small skin-barrier trial) versus a handful of isolate preclinical signals (antiparasitic, anticancer, bitter-receptor). The load-bearing caveat is compound-page discipline — no human isolate data, and a polar glucoside whose oral pharmacokinetics are uncharacterised.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. There are no human isolate data, so scores stay modest by design; the digestive-bitter row rests on the whole herb, not the isolate.

01Antileishmanial (Topoisomerase I)Shaky36%Isolate: enzyme inhibition + infected-hamster efficacy (vesicular delivery) ^{1,2Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}

02Digestive Bitter TonicShaky32%Whole-herb tradition; amarogentin as the TAS2R potency-driver, not a dosed isolate ^{5,6,7Reference 5Behrens M et al. · 2009The human bitter taste receptor hTAS2R50 is activated by the two natural bitter terpenoids andrographolide and amarogentinView study →Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}

03Anticancer / Pro-ApoptoticShaky30%Isolate: mouse skin (COX-2↓) + liver-cancer (p53↑/hTERT↓) apoptosis models ^{3,4Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →Reference 4Huang C et al. · 2017AnimalAmarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in miceView study →}

04Skin Barrier & Extraoral Bitter ReceptorsShaky26%Whole Gentiana lutea extract in keratinocytes + a 33-volunteer skin trial; isolate TAS2R binding ^{6Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →}

Mechanisms

The two load-bearing isolate mechanisms are topoisomerase-I inhibition (the antileishmanial identity) and a p53-up / hTERT-down, COX-2-down apoptotic program (the anticancer identity). The TAS2R agonism explains both the extreme bitterness and the extraoral (gut/skin) signalling; the biosynthetic/defence row is plant biology, not human pharmacology.

Pharmacokinetics

Amarogentin is a large, polar secoiridoid glucoside (a secoiridoid core esterified with a substituted biphenyl-carboxylic acid), and the honest position is that its human pharmacokinetics are essentially uncharacterised — there is no dedicated ADME dataset here for Cmax, half-life or oral bioavailability. By analogy with its co-occurring secoiridoids, oral absorption is expected to be poor: sibling glucosides such as loganin show very low oral bioavailability (~5% in rats), limited by intestinal first-pass metabolism. The strongest practical clue is the antileishmanial work itself — in-vivo efficacy required liposomal/niosomal delivery rather than free oral dosing ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}, consistent with a molecule that is not readily bioavailable as-is. The standard secoiridoid caveat therefore applies with force: micromolar in-vitro potency substantially overstates what an oral dose would deliver, and the molecule is better understood as the bitter marker of a whole-herb effect than as a stand-alone oral drug.

Clinical Trials

There are no controlled trials of isolated amarogentin. Human evidence is whole-herb: gentian’s long use as a digestive bitter, and a small (33-volunteer) skin trial of a Gentiana lutea extract (not the isolate) for epidermal barrier/lipid content ^{6Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →}. The antileishmanial and anticancer findings are entirely preclinical.

Last checked: July 2026.

Isolate vs. Plant Studies

The two evidence bases point in different directions and are not interchangeable. The human evidence is whole gentian — the centuries-old digestive-bitter tradition and the Gentiana lutea extract skin trial ^{6,7Reference 6Wölfle U et al. · 2017In vitroThe herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivoView study →Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →} — where amarogentin is present but is one constituent among many (alongside gentiopicroside and the xanthones) and is quantified as the bitterness marker rather than dosed as a drug. The isolate evidence, by contrast, is genuinely the pure molecule: the Leishmania topoisomerase-I inhibition ^{1Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →}, the hamster antileishmanial study ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}, and the skin- and liver-cancer apoptosis models ^{3,4Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →Reference 4Huang C et al. · 2017AnimalAmarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in miceView study →} all test amarogentin itself. That is an attributional strength on the mechanism side — but it is all in-vitro/rodent, and it inverts into a weakness on translation, because the isolate has no human data and (per the antileishmanial delivery problem) is not obviously bioavailable by mouth. The correct reading: whole-herb human tradition + real isolate mechanisms + no human isolate efficacy.

Its Role in Plants

Amarogentin is a secoiridoid — an iridoid glucoside whose cyclopentane ring has been oxidatively opened — belonging to the same biosynthetic lineage as loganin, gentiopicroside and oleuropein. Structurally it is distinguished from the simpler gentiopicroside by an ester linkage to a dihydroxy-methoxy biphenyl-carboxylic acid group; that aromatic ester is a large part of why amarogentin is so vastly more bitter than the un-esterified secoiridoid core.

Like other secoiridoid and iridoid glucosides (harpagoside, harpagide, oleuropein), its ecological role is chemical defence: bitter, deterrent glucosides stored in the root that discourage herbivory and browsing. As always, a molecule’s function as a plant defence compound is plant biology and does not predict what it does as a medicine.

Prevalence in Nature

Amarogentin occurs across the Gentianaceae, most famously in the root of yellow gentian (Gentiana lutea) — the pharmacopoeial bitter — where it is present at roughly 0.025–0.4% of the dried root ^{7Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. In the same root it is accompanied, and numerically dwarfed, by gentiopicroside (~1–4%), yet amarogentin dominates the bitterness because of its extreme per-molecule potency ^{7Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. It is also a characteristic secoiridoid of chirata (Swertia chirata) — the source used in most of the antileishmanial and anticancer isolate studies ^{1,3Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →} — and of other Gentiana and Swertia relatives.

Absolute content varies strongly with species, plant part, provenance and processing: the root/rhizome is the pharmacopoeial part, and leaves and flowers of Gentiana lutea also carry secoiridoids but in a different profile. A reliable cross-source concentration ranking beyond the gentian-root figure is not asserted here and is tracked as a gap.

Discovery & Synthesis

Amarogentin was characterised as the bitter principle of yellow gentian (Gentiana lutea) root — its name is a direct compound of amaro- (bitter) and gentian. Its structure, a secoiridoid glucoside esterified with a substituted biphenyl-carboxylic acid, was established through twentieth-century natural-product chemistry on the gentian and Swertia bitters. In the parasitology literature it was re-isolated from Swertia chirata by activity-guided fractionation against Leishmania topoisomerase I, which yielded amarogentin alongside amaroswerin and sweroside ^{1Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →}.

Manufacture is by extraction, not synthesis: amarogentin is obtained from gentian or Swertia material for use as a reference bitter and research compound. Total synthesis of the intact ester glucoside is not the practical supply route — as with other abundant plant glucosides, isolation from the source plant is far more tractable than de-novo synthesis.

Patents: not yet researched.

Toxicity & Safety

Amarogentin carries a low flag. It is the trace bitter marker of gentian, a root used for centuries as a food-grade digestive bitter (tinctures, aperitifs, tonics) with a long tolerability record at the low amounts delivered by bitters, and the one in-vivo isolate study that looked for toxicity — the infected-hamster antileishmanial work — reported no toxicity on blood pathology and liver-enzyme panels ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}. The rating stays off “none” for evidentiary reasons: there is no comprehensive isolate toxicology package (no definitive LD50, genotoxicity or repeat-dose dataset) for pure amarogentin, and its intense bitterness makes meaningful oral quantities self-limiting anyway.

Safety at a Glance

✅ Low / no toxicity

• A long-used, food-grade bitter constituent. The bitterness-defining trace compound of gentian root, used for centuries in bitters and digestive preparations; an in-vivo study reported no toxicity ^{2,7Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}.
• Exposure is whole-herb and tiny. People meet amarogentin as a trace constituent of gentian bitters, not as a concentrated isolate, and its extreme bitterness makes large oral doses self-limiting.
• No comprehensive isolate toxicology. No definitive LD50, genotoxicity or repeat-dose package for the pure molecule; safety is inferred from the whole herb, not established for the isolate.
• In-vitro potency overreads oral exposure. As a polar secoiridoid glucoside with no characterised oral PK (and vesicular delivery needed for in-vivo antileishmanial effect), cell/high-dose findings do not transfer cleanly to an oral dose ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}.

Full Safety & Interactions Detail

Amarogentin reads as a low-toxicity secoiridoid glucoside — the trace bitter principle of gentian root, a food-grade botanical with a long history in digestive bitters, and the infected-hamster antileishmanial study explicitly found no toxicity on blood pathology and liver enzymes for the vesicular formulations tested ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}.

The caveats are evidentiary rather than observed harms. First, there is no comprehensive isolate toxicology — no definitive LD50, genotoxicity or repeat-dose organ-toxicity dataset for pure amarogentin — so its safety is inferred from the whole herb, not demonstrated for the molecule. Second, formal drug-interaction data are absent: no specific CYP-inhibition or transporter profile is characterised here, so interaction potential is uncharacterised rather than shown to be low. Third, its oral pharmacokinetics are unknown and probably poor (see Pharmacokinetics), which both limits real-world isolate exposure and means preclinical or parenterally-delivered findings do not translate straightforwardly to oral use ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}.

Reproductive note (prose only). No dedicated reproductive- or developmental-toxicity dataset exists for isolated amarogentin. Traditional caution around bitter digestive herbs in pregnancy is sometimes noted for gentian at the herb level; any such pregnancy/lactation decision belongs to the source-herb or product page where intake is decided, not to this molecule page.

Dosage

There is no established or recommended human dose for isolated amarogentin — it has never been administered to people as an isolate for therapy. The cited figures are preclinical research values: micromolar concentrations in cell and enzyme assays ^{1,3,4Reference 1Ray S et al. · 1996Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovaniView study →Reference 3Saha P et al. · 2006AnimalAmarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis modelView study →Reference 4Huang C et al. · 2017AnimalAmarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in miceView study →}, and the hamster antileishmanial doses delivered in liposomal/niosomal form rather than orally ^{2Reference 2Medda S et al. · 1999Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal formsView study →}. Human intake is indirect and small, through whole gentian-root bitters — tinctures, aperitifs and appetite/digestive preparations standardised (where at all) to the herb’s overall bitterness, in which amarogentin is the trace potency-driver rather than a dosed active ^{7Reference 7Ponticelli M et al. · 2023Systematic reviewThe healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic reviewView study →}. Its extreme bitterness also makes any large oral quantity self-limiting. These are doses studied in research and are not a personal recommendation.

References

1. Ray S, Majumder HK, Chakravarty AK, Mukhopadhyay S, Gil RR, Cordell GA (1996). Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/8984149/
2. Medda S, Mukhopadhyay S, Basu MK (1999). Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. Journal of Antimicrobial Chemotherapy. https://pubmed.ncbi.nlm.nih.gov/10590280/
3. Saha P, Mandal S, Das A, Das S (2006). Amarogentin can reduce hyperproliferation by downregulation of Cox-II and upregulation of apoptosis in mouse skin carcinogenesis model. Cancer Letters. https://pubmed.ncbi.nlm.nih.gov/16517061/
4. Huang C, Li R, Zhang Y, Gong J (2017). Amarogentin induces apoptosis of liver cancer cells via upregulation of p53 and downregulation of human telomerase reverse transcriptase in mice. Technology in Cancer Research & Treatment. https://pubmed.ncbi.nlm.nih.gov/27402632/
5. Behrens M, Brockhoff A, Batram C, Kuhn C, Appendino G, Meyerhof W (2009). The human bitter taste receptor hTAS2R50 is activated by the two natural bitter terpenoids andrographolide and amarogentin. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/19817411/
6. Wölfle U, Haarhaus B, Seiwerth J, Cawelius A, Schwabe K, Quirin KW, Schempp CM (2017). The herbal bitter drug Gentiana lutea modulates lipid synthesis in human keratinocytes in vitro and in vivo. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/28829355/
7. Ponticelli M, Lela L, Moles M, Mangieri C, Bisaccia D, Faraone I, Falabella R, Milella L (2023). The healing bitterness of Gentiana lutea L., phytochemistry and biological activities: a systematic review. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/36423749/

View all 7 references▾